NASDAQ · SNGX
Healthcare · Biotechnology
$0.40
Up+$0.02 (+5.50%)
Updated Aug 22, 2026, 12:13 PM
SID Score
3.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
SNGX closed at $0.40 after 21 trading sessions, up 8.00% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $0.38 | $0.4219 | $0.38 | $0.401 | 989.18K |
| Aug 20, 2026 | $0.38 | $0.39 | $0.38 | $0.3801 | 93.98K |
| Aug 19, 2026 | $0.3857 | $0.3948 | $0.38 | $0.3811 | 106.48K |
| Aug 18, 2026 | $0.3828 | $0.3979 | $0.3809 | $0.396 | 133.88K |
| Aug 17, 2026 | $0.3922 | $0.3922 | $0.38 | $0.3812 | 113.21K |
| Aug 14, 2026 | $0.3789 | $0.4012 | $0.3789 | $0.40 | 333.47K |
| Aug 13, 2026 | $0.3931 | $0.3931 | $0.3809 | $0.3809 | 135.79K |
| Aug 12, 2026 | $0.38 | $0.395 | $0.38 | $0.39 | 127.09K |
| Aug 11, 2026 | $0.3803 | $0.3921 | $0.3775 | $0.3865 | 95.43K |
| Aug 10, 2026 | $0.399 | $0.40 | $0.3775 | $0.3775 | 144.71K |
| Aug 7, 2026 | $0.38 | $0.3969 | $0.3785 | $0.3921 | 131.73K |
| Aug 6, 2026 | $0.3774 | $0.3936 | $0.3774 | $0.3788 | 132.29K |
| Aug 5, 2026 | $0.39 | $0.3977 | $0.377 | $0.3829 | 164.41K |
| Aug 4, 2026 | $0.3776 | $0.3827 | $0.377 | $0.377 | 249.21K |
| Aug 3, 2026 | $0.3797 | $0.3854 | $0.368 | $0.3775 | 197.54K |
| Jul 31, 2026 | $0.3734 | $0.395 | $0.3631 | $0.3739 | 325.18K |
| Jul 30, 2026 | $0.37 | $0.376 | $0.3548 | $0.375 | 255.85K |
| Jul 29, 2026 | $0.36 | $0.37 | $0.3506 | $0.3616 | 198.15K |
| Jul 28, 2026 | $0.37 | $0.37 | $0.3529 | $0.3616 | 418.32K |
| Jul 27, 2026 | $0.3713 | $0.3799 | $0.3574 | $0.3619 | 249.41K |
| Jul 24, 2026 | $0.37 | $0.3793 | $0.36 | $0.3713 | 151.23K |
The latest Smart Investors Daily articles mentioning SNGX.
SNGX research
Company profile and research snapshot.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 16, 2025 | Alliance Global Partners | Buy | — |
| Dec 4, 2020 | B. Riley FBR | Buy | — |
| Jul 28, 2020 | Dawson James | Neutral | — |
| Jan 31, 2018 | H.C. Wainwright | Neutral | — |
| Aug 14, 2017 | Maxim Group | Buy | — |
No generated briefing is available yet.
Benzinga · Mar 10, 2026
Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced
Yahoo · Feb 26, 2026
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) provided a positive recommendation on the Company's request for orphan drug designation for dusquetide (the active pharmaceutical ingredient in SGX945) for the treatment of Behçet's Dise
Benzinga · Feb 26, 2026
Yahoo · Dec 3, 2025
NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- via BioMedWire: — Soligenix Inc. (NASDAQ: SNGX) today announces its placement in an editorial published by BioMedWire ("BMW"), one of 75+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. To view the full publication, “Chronic Rare Diseases in an Aging America: Why HyBryte and F
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning SNGX.
